how dangerous are glp-1 Medications Infographic GLP-1 Genetics: How Genes Affect

Unlike broader pharmacological agents, these peptides act at the level of gene expression and protein synthesis, helping cells maintain or regain their optimal function

Source: Alzheimers Association A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported today at the Alzheimers Association International Conference (AAIC ) 2024, in Philadelphia and online

The short answer: it depends on your baseline

Additional Research and Background These sources provide related context and are not presented as support for a specific statement above

Histological assessment and scoring were performed by a pathologist blinded to the study conditions